Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Anticoagulants article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
The oral anticoagulants available in the UK are warfarin, acenocoumarol, phenindione, dabigatran etexilate, rivaroxaban, edoxaban and apixaban.
- Warfarin continues to be the most widely used oral anticoagulant but the use of the newer oral anticoagulants (dabigatran etexilate, rivaroxaban, edoxaban and apixaban) is increasing.
- Warfarin antagonises vitamin K (needed for the synthesis of clotting factors) and takes 2-3 days to exert its full effect.
- In some situations heparin needs to be given for immediate anticoagulation, whilst waiting for the INR to get into the required range.
- Dabigatran etexilate, rivaroxaban, edoxaban and apixaban are relatively newer oral anticoagulants. Dabigatran etexilate is a direct thrombin inhibitor, whilst rivaroxaban, edoxaban and apixaban inhibit activated factor X (factor Xa).
- Dabigatran etexilate, rivaroxaban, edoxaban and apixaban do not require monitoring of the INR.
Indications and targets
Anticoagulation recommendations[2, 3, 4, 5, 6, 7, 8, 9, 10, 11]
Which anticoagulant to use and the international normalised ratio (INR)
Proximal deep vein thrombosis (DVT).
Warfarin - 2.5 (3.5 for pulmonary embolus sustained whilst already on warfarin with INR above 2).
Rivaroxaban or edoxaban are options for the treatment of DVT and pulmonary embolism in adults.
|At least three months if risk factors are temporary but at least six months if they are permanent or cause unknown.|
|Prophylaxis of venous thromboembolism (VTE)|
Warfarin not indicated.
Rivaroxaban and edoxaban are options for the prevention of recurrent DVT and pulmonary embolism in adults.
Dabigatran - start within 1-4 hours of surgery and continue for 10 days after knee replacement and for 28-35 days after hip replacement.
Apixaban - start 12-24 hours after surgery and continue for 32-38 days (hip surgery) or 10-14 days (knee surgery).
|Calf DVT.||Warfarin - 2.5.||At least six months if temporary risk factors. Long-term anticoagulation may be appropriate.|
|Recurrence of DVT (whilst on warfarin).||Warfarin - 3.5.||Long-term.|
|Recurrence of DVT (when not on warfarin).|
Warfarin - 2.5.
Dabigatran etexilate is recommended as an option for treating and for preventing recurrent DVT and pulmonary embolism in adults.
|At least six months if temporary risk factors. Long-term anticoagulation may be appropriate.|
|Mitral stenosis or regurgitation - for those who have any of the following:|
atrial fibrillation, history of systemic embolism, left atrial thrombus, an enlarged left atrium.
|Warfarin - 2.5.||Long-term.|
|Inherited thrombophilia (symptomatic), antiphospholipid syndrome.||Warfarin - 2.5.||Long-term.|
|Paroxysmal nocturnal haemoglobinuria (PNH).||Warfarin - 2.5 for patients with a high proportion of PNH clones (greater than 50%) and a platelet count greater than 100 x 109/L. Anticoagulation may be appropriate for patients with lower indices if additional risk factors are present.||Long-term.|
|Atrial fibrillation.||Warfarin - 2.5.|
Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age ≥75 years, diabetes mellitus, or hypertension: dabigatran etexilate, rivaroxaban, edoxaban or apixaban - no need to monitor INR.
|Long-term. NB: recent National Institute for Health and Care Excellence (NICE) guidance on the use of alternatives to warfarin, ie dabigatran, rivaroxaban and apixaban (see below).|
|Cardioversion.||Warfarin - 2.5 (cardioversion is generally cancelled if INR is <2 on the day, so to minimise this it may be appropriate to use 3 as a target before the procedure).||Three weeks before and four weeks after cardioversion.|
|Mural thrombus.||Warfarin - 2.5.||Depends on assessment of individual patient risk.|
|Dilated cardiomyopathy.||Warfarin - 2.5.||Long-term.|
|Arterial grafts (if needed).||Antiplatelet drugs are first-line. If additional anticoagulation with warfarin is considered necessary, target INR should be 2.5.||Long-term.|
|Coronary thrombosis.||Warfarin - 2.5.||Depends on assessment of individual patient risk.|
Bileaflet aortic 3.0.
Bileaflet mitral 3.5.
Tilting disk (any site) 3.0.
Caged ball/disk (any site) 3.5.
If type not known, aim for 3.0 (aortic) or 3.5 (mitral).
|Coronary artery graft.||Not indicated.|
|Coronary angioplasty and stents.||Not indicated.|
NB: the use of warfarin to treat thromboses has more evidence base than the use of heparin.
When to use aspirin plus warfarin
The following are recommended:
- Patients on an antiplatelet agent for primary prevention of cardiovascular disease (CVD) or peripheral arterial disease or previous ischaemic stroke should have this stopped if they develop an indication for warfarin.
- Patients on aspirin or clopidogrel for secondary prevention of CVD with stable coronary heart disease (one definition being symptom-free for >12 months following acute myocardial infarction (MI)) should also have this stopped if they develop an indication for warfarin.
- For patients who have had an acute coronary syndrome (ACS) within in the previous year:
- Those on a single antiplatelet agent should continue this even if they have to start oral anticoagulation. The antiplatelet agent should be stopped 12 months post-ACS.
- Those on dual antiplatelets following ACS or insertion of drug-eluting stents, who then need to start oral anticoagulants, should be assessed with cardiological and haematological specialists and an attempt made to determine the risk versus benefits of triple therapy.
- If a patient on warfarin develops the need for a coronary artery stent then bare metal stents are preferred, as triple therapy will only be needed for four weeks, following which clopidogrel can be stopped (and aspirin can be stopped at 12 months provided the patient remains cardiovascularly stable).
- Patients on aspirin and clopidogrel, following an ACS or stent placement, who develop an indication for warfarin should be carefully assessed for bleeding risk and discussed with their cardiologist, with a view to introducing warfarin and minimising the duration of triple therapy.
- When combined warfarin and single antiplatelet agent are indicated, consideration should be given to use of aspirin given the higher bleeding risk associated with clopidogrel.
- In patients undergoing heart valve replacement, continuation of aspirin in patients commencing warfarin confers increased protection against MI and stroke, but at the price of increased bleeding risk.
Dabigatran etexilate, rivaroxaban, apixaban and edoxaban
- Treatment of DVT and pulmonary embolism[2, 3, 4, 11, 14]:
- Dabigatran etexilate is recommended as an option for treating recurrent DVT and pulmonary embolism in adults.
- Rivaroxaban and edoxaban are also options for the treatment of DVT and pulmonary embolism.
- Prevention of VTE[2, 3, 4, 7, 11]:
- Dabigatran etexilate, rivaroxaban and apixaban are licensed for use in adults after total hip replacement or total knee replacement surgery.
- Dabigatran etexilate is recommended as an option for preventing recurrent DVT and pulmonary embolism in adults.
- Rivaroxaban and edoxaban are options for the prevention of recurrent DVT and pulmonary embolism in adults.
- Atrial fibrillation[8, 9, 10]:
- Dabigatran etexilate, rivaroxaban,apixaban and edoxaban are recommended as alternatives to warfarin, in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
- They are as effective as warfarin in the reduction of the relative risk of stroke and systemic embolisation in patients with atrial fibrillation. Their use is limited to non-valvular atrial fibrillation with one or more of the following risk factors:
- For dabigatran etexilate:
- Previous stroke.
- Previous transient ischaemic attack.
- Previous systemic embolism.
- Left ventricular ejection fraction below 40%.
- Symptomatic heart failure of New York Heart Association (NYHA) class 2 or above.
- Age 75 years or older.
- Age 65 years or older with one of the following: diabetes mellitus, coronary artery disease or hypertension.
- For rivaroxaban, apixaban and edoxaban:
- Congestive heart failure.
- Age 75 years or older.
- Diabetes mellitus.
- Prior stroke or transient ischaemic attack.
- For dabigatran etexilate:
- The decision about whether to start treatment with dabigatran etexilate, rivaroxaban, apixaban or edoxaban should follow a discussion between the clinician and patient regarding the risks and benefits compared with warfarin.
- NICE recommends two dose options for dabigatran etexilate - a regular dose and a lower dose for those patients at high risk of bleeding.
- Dabigatran etexilate, rivaroxaban apixaban and edoxaban have previously all been associated with lower rates of intracranial haemorrhage at the cost of possible increase in gastrointestinal bleeding. However, a study comparing the safety of direct oral anticoagulants (DOACs) and warfarin in the treatment of VTE identified 59,525 adults (12,489 DOAC users and 47,036 warfarin users) with a new diagnosis of VTE and a prescription for a DOAC or warfarin within 30 days of diagnosis. 1,967 (3.3%) had a major bleed and 1,029 (1.7%) died during the follow-up period. The risk of major bleeding was similar for DOACs compared with warfarin use. Bleeding rates at 30 days ranged between 0.2% and 2.9% for DOACs and 0.2% and 2.9% for warfarin. Bleeding rates at 60 days ranged between 0.4% and 4.3% for DOACs and 0.4% and 4.3% for warfarin. No difference was found in the risk of death for DOACs compared with warfarin use. Results remained unchanged after further analyses, including when a longer period of follow-up (180 days) was used.
Dr Sarah Jarvis, 10th August 2021
Update to NICE TAGs on DOACs for AF stroke prevention
NICE has updated its technological appraisal guidances for apixaban, dabigatran, edoxabanand rivaroxabanfor the prevention of stroke and systemic embolism in people with AF. The licensed indications have not changed but NICE stresses for each the importance of:
- Having an informed discussion on the relative risks and benefits of each DOAC before initiating treatment.
- Discussing the risks and benefits of switching from warfarin to a given DOAC, taking into account their level of INR control. before proceeding with a switch.
The Medicines and Healthcare products Regulatory Agency (MHRA) revised its list of contra-indications in 2009 as a result of Yellow Card reports received over the years. The current list is as follows:
- Known hypersensitivity to warfarin or to any of the excipients.
- Haemorrhagic stroke.
- Clinically significant bleeding.
- Within 72 hours of major surgery with risk of severe bleeding.
- Within 48 hours postpartum.
- Pregnancy (first and third trimesters, can cause congenital malformations and fetal death).
- Drugs where interactions may lead to a significantly increased risk of bleeding - eg, antiplatelet drugs, non-steroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors (SSRIs), venlafaxine or duloxetine.
- Uncorrected major bleeding disorder (eg, haemophilia, chronic kidney disease).
- Potential bleeding lesions - eg, active peptic ulcer, oesophageal varices.
- Uncontrolled severe hypertension.
- An unco-operative or unreliable patient.
- A patient at risk of repeated falls.
The MHRA was been contacted by King's College Hospital in London regarding their concerns over an apparent increase in the number of patients taking warfarin found to have elevated INR values during the COVID-19 pandemic. This was thought to be multifactorial. The MHRA advises that acute illness may exaggerate the effect of warfarin tablets and necessitate a dose reduction.
NB: treatment with warfarin is not contra-indicated in breastfeeding.
Ideally, the baseline prothrombin time should be used to assess dosage but if the clinical situation requires it, initiation should not be delayed. Guidance for acute VTE recommends that parenteral anticoagulation continue for at least five days and until the INR is ≥2 (whichever is the longer). If rapid anticoagulation is required, a loading dose of 5-10 mg should be given on the first day. The subsequent dosage regime depends on the prothrombin time expressed as the INR.
Computer-assisted dosing is superior to manual dosing. When initiating an oral anticoagulant, consider the existence of comorbidity or therapy likely to increase the risk of bleeding - for example:
- Renal impairment.
- Abnormal LFTs.
- Cardiac failure.
- Low body weight.
- Parenteral feeding.
- Acute illness.
- Vitamin K deficiency.
- Drugs likely to potentiate the effect of anticoagulation.
- Advanced age.
If any condition is present which is likely to potentiate the effect of warfarin, or if the baseline prothrombin time is prolonged, consider reducing the first loading dose.
Aim for an INR within 0.5 units of the target.
In atrial fibrillation there is no need to increase warfarin rapidly. An initial dose of 2-3 mg a day achieves therapeutic coagulation in most people in 3-4 weeks.
Patients with protein C deficiency are at risk of developing skin necrosis with warfarin. The loading dose should therefore be omitted at initiation. A similar cautious approach should be instigated in patients with protein S deficiency.
People on oral anticoagulants need regular monitoring of INR. INR is checked daily until in the therapeutic range, twice a week for 1-2 weeks, weekly until stable, then every 6-12 weeks.
Change in a patient's condition - eg, liver disease, intercurrent illness, a new drug started - necessitates more frequent testing.
Enhancement of warfarin effect can occur in:
- Loss of weight.
- Acute illness.
- Cessation of smoking.
Reduction of warfarin effect can occur in:
- Weight gain.
In patients with unstable INRs, supplementation of the diet with 100-150 micrograms of vitamin K may improve anticoagulant control.
Near-patient testing (NPT) and patient self-management (PSM)
INR monitoring is normally managed by local anticoagulant clinics but, with appropriate training, self-management using a portable coagulation monitor (eg, CoaguChek® S system) can be safe and reliable and much more convenient for many patients. A worrying trend is for patients to buy monitors directly from the manufacturer and use them without proper training. It is hoped that the manufacturers can be engaged to encourage patients to discuss the options with their GP prior to purchase. The Warfarin SMART study found that patient self-management performed at least as well as usual care in maintaining the INR within the target range, without any safety concerns.
- Patients should conduct NPT, with or without PSM, within a managed anticoagulation clinic programme.
- The programme should aim for the same standards of care as a hospital clinic.
- Patients should be assessed for capability - only patients able to follow the same total quality management procedures as hospitals should undertake NPT ± PSM.
- Patients should be audited regularly for comparison with laboratory results, proportion of INRs in range and adverse events.
Patients should be advised to:
- Take the prescribed dose at the same time, daily.
- Report any bruising or bleeding immediately.
- Attend for blood tests as advised.
- Avoid pregnancy - ensure adequate contraception.
- Avoid aspirin - use paracetamol for pain.
- Avoid contact sports and activities carrying a risk of head injury.
- Remind medical and dental carers of anticoagulant use.
- Avoid non-steroidal anti-inflammatory drugs (NSAIDS) - diclofenac, meloxicam can be used with care.
- Keep the primary care organisation booklet up to date.
Complications and reasons to discontinue warfarin
The main adverse effect of warfarin is haemorrhage. Risk factors for haemorrhage in patients taking warfarin include:
- High intensity of anticoagulation (INR >4.0).
- Age ≥65 years.
- Highly variable INRs.
- History of gastrointestinal bleeding.
- Uncontrolled hypertension.
- Cerebrovascular disease.
- Serious heart disease.
- Risk of falling.
- Renal insufficiency.
- Concomitant drugs.
Other adverse effects include hypersensitivity, rash, alopecia and diarrhoea. See monograph for full list.
Managing haemorrhage and/or a high INR[1, 12]
If the patient has life-threatening bleeding (eg, intracranial or gastrointestinal haemorrhage), hospital admission is indicated. Hospital management involves giving phytomenadione (vitamin K1) 5-10 mg by slow intravenous injection, together with dried prothrombin complex (factors II, VII, IX and X) 30-50 units/kg. Fresh frozen plasma 15 mg/kg should be used if dried prothrombin complex cannot be obtained but is suboptimal. In other cases, manage as below:
- INR above 8 without bleeding or with only a minor bleed (eg, haematuria or epistaxis) - stop warfarin, administer vitamin K1, using the intravenous solution orally (unlicensed use) 2.5-5 mg by mouth, or 0.5-1 mg by intravenous injection slowly. Check INR again 24 hours later; if more than 0.5 above target value, give another dose of vitamin K1. Restart warfarin when INR <5.0.
- INR of 5-8, no bleeding - stop warfarin. If minor bleed, administer vitamin K1 1-2.5 mg by mouth, using intravenous preparation orally. In either case, warfarin can be started again when INR <5.0.
A high INR is often due to a drug interaction (see monograph for a full list). If possible, prescribe drugs that do not interact with warfarin. Note that considerable variation exists between drugs in the same class (eg, antibiotics).
If the haemorrhage occurred when the warfarin level was in the therapeutic range, consider an underlying cause such as unsuspected renal or gastrointestinal tract pathology.
Managing a low INR
- Ask the patient if they have missed any doses.
- Consider increasing the dose temporarily and adding a booster dose if necessary. Measure the INR again 2-3 days later.
There was initial concern that stopping anticoagulation abruptly would cause a rebound hypercoagulable state. This has not been confirmed by prospective trials and it is now known that warfarin can be stopped without any associated clinical risk, once therapy has been completed.
- Warfarin is enhanced by alcohol, allopurinol, paracetamol, SSRIs, lipid-regulating drugs, cranberry juice, influenza vaccine and many other drugs and is reduced by oral contraceptives and St John's wort. The effect of other herbal and complementary remedies should not be forgotten.
- Advise people on warfarin to check with their pharmacist that any new medicine they are prescribed or buy is OK to take with warfarin.
- Reassess the need for warfarin regularly; a person's cardiovascular risk and the risk of bleeding will change over time.
Managing unavoidable interactions
- If an interacting drug will be used for less than five days, often no dosage change is necessary. Omission of one full warfarin dosage may be prudent with known potentiating drugs.
- If an interacting drug will be used for more than five days, check the INR one week after starting therapy and adjust the warfarin dose accordingly. The INR should also be monitored when an interacting drug is stopped.
- During amiodarone loading, reduce warfarin by half and check INR weekly.
- Major changes in diet (especially involving salads and vegetables) consumption may affect warfarin control.
Special clinical scenarios
- Ischaemic stroke in atrial fibrillation patients: the risk of early recurrent embolism of haemorrhagic stroke is small, so a break in treatment is justified in order to minimise the risk of secondary haemorrhage. The break should be for 2-14 days depending on the size of the infarct and the blood pressure.
- Intravenous drug users: thrombosis of the iliofemoral vein is common in this patient group. The use of low molecular weight heparin (LMWH) should be considered as an alternative to oral warfarin, particularly if monitoring is difficult because of the patient's lifestyle or there is difficulty in accessing veins.
- Cancer patients with VTE: LMWH gives a better risk:benefit profile (recurrent thromboembolism versus bleeding) than warfarin and should be considered first-line in these patients. DOACs are also an option. Selection of OA should be guided by the wishes of the patient and the type of cancer.
- Patients with peptic ulcers: patients with active peptic ulcers are at increased risk of bleeding when on warfarin, so should be reviewed regularly, advised how to recognise bleeding and informed what to do should bleeding occur.
- Head injuries:
- NICE recommends that patients (adults and children) who have sustained a head injury, with no other indications for a CT head scan and who are having anticoagulant treatment, should have a CT head scan within eight hours of the injury.
- Patients on oral anticoagulants are at an increased risk of intracranial bleed following a head injury and a low threshold to perform a CT head scan is needed. If there is a high suspicion of an intracranial bleed then the INR should be reversed without delay.
- There is also a risk of delayed intracranial bleed even if the initial CT scan was normal. Therefore, it is recommended that the INR be kept close to 2.0 for the first four weeks following a significant head injury.
- Managing anticoagulation prior to surgery[12, 25]:
- Warfarin should be stopped for five days before an elective procedure if anticoagulation needs to be discontinued.
- Patients with VTE more than three months earlier can usually be given post-operative prophylactic dose LMWH (or a suitable alternative) rather than bridging therapy (pre-operative replacement of warfarin with 10-12 days of a short-acting anticoagulant such as LMWH).
- Patients at very high risk of recurrent VTE, such as patients with a previous VTE whilst on therapeutic anticoagulation who now have a target INR of 3·5, and patients who have had VTE less than three months previously should be considered for bridging.
- Patients with atrial fibrillation who have a CHADS2 score of ≤4 and who have not had a stroke or transient ischaemic attack (TIA) in the preceding three months should not receive bridging.
- Patients with a bileaflet aortic mechanical heart valve (MHV) with no other risk factors do not require bridging whilst it should be considered in all other MHV patients (2C).
- We recommend that postoperative bridging is not started until at least 48 hours after high bleeding risk surgery (1C).
- The timing of re-introduction of warfarin depends on the risk of haemorrhage after surgery. In most cases this can occur as soon as the patient can take medication orally but, for any high bleeding risk surgery, it is recommended to wait for at least 48 hours .
- Thyroid disease: myxoedema and thyrotoxicosis can both affect warfarin levels and patients should be closely monitored at the time of initiation.
Compliance can be improved by:
- Prescribing the smallest number of tablets each day.
- Use of daily dosing rather than alternate day dosing if possible.
- Avoiding using half tablets, as patients may find it difficult to break tablets exactly in half.
Dabigatran etexilate, rivaroxaban, apixaban and edoxaban[26, 27, 28]
Rivaroxaban, apixaban, dabigatran etexilate and edoxaban may be options for patients who are unable to tolerate or comply with warfarin and its therapeutic drug monitoring.
Cautions and/or contra-indications
- Rivaroxaban, apixaban and dabigatran etexilate are contra-indicated in any clinical scenario associated with enhanced coagulopathy as for warfarin - eg, hepatic disease. Rivaroxaban, apixaban and dabigatran etexilate are contra-indicated in severe renal impairment. Edoxaban is contra-indicated in end-stage renal disease.
- Rivaroxaban, apixaban, dabigatran etexilate and edoxaban are contra-indicated in paediatric populations (ie under the age of 18 years), pregnancy and lactation, due to inadequate evidence of safety and efficacy.
- Rivaroxaban, apixaban and edoxaban interact with medications which inhibit or induce both CYP3A4 and/or P-gp - eg, ketoconazole.
- In comparison, dabigatran etexilate is not affected by the cytochrome P450 medications but does interact with drugs that effect P-gp. For example, amiodarone, verapamil and clarithromycin are P-gp inhibitors, which would lead to increased dabigatran levels. The converse is true of P-gp inducers - eg, rifampicin, carbamazepine and phenytoin. Close clinical surveillance is necessary when these drugs are co-administered, especially if mild-to-moderate renal impairment is also present.
- SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs) also lead to increased bleeding risk with dabigatran etexilate.
- Care should also be taken when either drug is co-administered with NSAIDs and platelet aggregator inhibitors.
None of these drugs requires formal therapeutic drug monitoring but by their nature they can lead to increased bleeding and thus monitoring Hb may be advised. Despite this, with dabigatran etexilate the measurement of activated partial thromboplastin time may help in certain scenarios.
Rivaroxaban, apixaban and edoxalate:
- Bleeding and anaemia can occur.
- Dizzy spells, and headache have been reported so there may be a mild effect on the ability to drive and the use of machines. Likewise, syncope has been reported with rivaroxaban and apixaban but not edoxalate.
- Nausea and gastrointestinal upset.
- Peripheral oedema and fever have also been reported with rivaroxaban and apixaban but not edoxalate.
- Abnormal renal tests and LFTs.
- Nausea and gastrointestinal discomfort, including diarrhoea.
- Abnormal LFTs.
NB: idarucizumab (Praxbind®) was released in January 2016. This rapidly reverses the anticoagulant effect of dabigatran
Further reading and references
Measurement of non-Coumarin anticoagulants and their effects on tests of Haemostasis; Guidance from the British Committee for Standards in Haematology (2014)
Atrial fibrillation; NICE CKS, May 2021 (UK access only)
DVT prevention for travellers; NICE CKS, August 2018 (UK access only)
British National Formulary (BNF); NICE Evidence Services (UK access only)
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism; NICE Technology Appraisal Guidance, June 2013
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism; NICE Technology Appraisal Guidance, July 2012
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism; NICE Technology Appraisal Guidance, December 2014
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults; NICE Technology Appraisal Guidance, January 2012
Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation; NICE Technology Appraisal Guidance - last updated July 2021
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults; NICE Technology Appraisal Guidance, April 2009
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation; NICE Technology Appraisal Guidance - last updated July 2021
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation; NICE Technology Appraisal Guidance - last updated July 2021
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation; NICE Technology Appraisal Guidance - last updated July 2021
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism; NICE Technology appraisal guidance, August 2015
Guidelines on oral anticoagulation with warfarin, British Committee for Standards in Haematology (2011)
Zhang P, Li J, Wu C, et al; Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. Herz. 2017 May42(3):295-306. doi: 10.1007/s00059-016-4470-0. Epub 2016 Oct 26.
Edoxaban - Lixiana®, Summary of Product Characteristics; Daiichi Sankyo UK Limited, electronic Medicines Compendium, November 2020.
Jun M, Lix LM, Durand M, et al; Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ. 2017 Oct 17359:j4323. doi: 10.1136/bmj.j4323.
Warfarin: changes to safety information; Medicines and Healthcare products Regulatory Agency, 2009 (archived content)
Medicines and Healthcare products Regulatory Agency; Warfarin and other anticoagulants – monitoring of patients during the COVID-19 pandemic, 2020.
Dignan R, Keech AC, Gebski VJ, et al; Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. Int J Cardiol. 2013 Oct 15168(6):5378-84. doi: 10.1016/j.ijcard.2013.08.054. Epub 2013 Aug 27.
Blann AD, Fitzmaurice DA, Lip GY; Anticoagulation in hospitals and general practice. BMJ. 2003 Jan 18
Anticoagulation - oral; NICE CKS, April 2021 (UK access only)
Shalansky S, Lynd L, Richardson K, et al; Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. 2007 Sep27(9):1237-47.
Russell M, Dawson D; Best evidence topic report. Low molecular weight heparin for intravenous drug users with deep vein thrombosis. Emerg Med J. 2004 Nov21(6):711. doi: 10.1136/emj.2004.019653.
O'Connell C, Escalante CP, Goldhaber SZ, et al; Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 Jan26(1):e8-e16. doi: 10.1002/onco.13584. Epub 2020 Dec 4.
Head injury: assessment and early management; NICE Clinical Guideline (January 2014, updated September 2019)
Keeling D, Tait RC, Watson H; Peri-operative management of anticoagulation and antiplatelet therapy. Br J Haematol. 2016 Nov175(4):602-613. doi: 10.1111/bjh.14344. Epub 2016 Oct 7.
Apixaban - Eliquis®, Summary of Product Characteristics (SPC); Bristol-Myers Squibb-Pfizer, electronic Medicines Compendium, Jul 2014
Dabigatran etexilate®; Summary of Product Characteristics (SPC), Boehringer Ingelheim Limited, electronic Medicines Compendium, Dec 2014
Summary of Product Characteristics (SPC); Rivaroxaban®, Bayer plc, electronic Medicines Compendium, Dec 2014